AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 OCT 1 - (NewsRx.com & NewsRx.net) -- Ichor Medical Systems, Inc., announced that it has licensed worldwide rights to the Interleukin-12 (IL-12) gene from The Wistar Institute, Philadelphia, Pennsylvania.
Ichor plans to develop clinical products combining its patented TriGrid electroporation delivery technology with IL-12 for use in cancer and vaccine applications.
IL-12 is a powerful cytokine that can be used to dramatically improve the body's immune responses to certain diseases.
Early on IL-12 held great promise for treating cancer, but the protein form administered systemically to patients in those early human trials had unacceptable side effects. Ichor scientists have now learned that when the IL-12 gene is inserted directly into the cancer cells using the TriGrid delivery system, the harmful side effects are eliminated and the anticancer response is vastly improved.
According to Ichor CEO Robert Bernard, "These preclinical findings have formed the basis for Ichor's decision to invest in the IL-12/TriGrid product combination. We are encouraged that several academic institutions ...